Literature DB >> 17203346

An unusual case of transitional cell carcinoma of renal pelvis presenting with brain metastases.

Surendra B Kolla1, Ashok K Hemal.   

Abstract

We report a rare case, who had presented with a constellation of neurological symptoms (due to multiple brain metastases), but without any urological symptoms, to the department of neurosurgery. The patient was managed with gamma knife stereotactic radiosurgery for the metastatic lesions. During an evaluation for primary, he was found to be having transitional cell carcinoma (TCC) of right renal pelvis, for which palliative radical nephroureterectomy was performed, following which he received four cycles of paclitaxel and carboplatin chemotherapy. The patient is alive with stable disease at 22-months follow-up.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17203346     DOI: 10.1007/s11255-006-9155-9

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  16 in total

Review 1.  Adjuvant treatment of brain metastases.

Authors:  F Lohr; A Pirzkall; H Hof; K Fleckenstein; J Debus
Journal:  Semin Surg Oncol       Date:  2001 Jan-Feb

2.  Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience.

Authors:  Arlene O Siefker-Radtke; Garrett L Walsh; Louis L Pisters; Yu Shen; David A Swanson; Christopher J Logothetis; Randall E Millikan
Journal:  J Urol       Date:  2004-01       Impact factor: 7.450

3.  Transitional cell carcinoma of renal pelvis with multiple cerebral metastases.

Authors:  J N Kabalin; F M Torti; F S Freiha
Journal:  Urology       Date:  1990-12       Impact factor: 2.649

4.  Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.

Authors:  C N Sternberg; A Yagoda; H I Scher; R C Watson; N Geller; H W Herr; M J Morse; P C Sogani; E D Vaughan; N Bander
Journal:  Cancer       Date:  1989-12-15       Impact factor: 6.860

5.  M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.

Authors:  C N Sternberg; A Yagoda; H I Scher; R C Watson; H W Herr; M J Morse; P C Sogani; E D Vaughan; N Bander; L R Weiselberg
Journal:  J Urol       Date:  1988-03       Impact factor: 7.450

6.  Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method.

Authors:  S N Sanghavi; S S Miranpuri; R Chappell; J M Buatti; P K Sneed; J H Suh; W F Regine; E Weltman; V J King; S J Goetsch; J C Breneman; P W Sperduto; C Scott; S Mabanta; M P Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-10-01       Impact factor: 7.038

7.  Management of high grade transitional cell cancer of the upper urinary tract.

Authors:  D M Murphy; H Zincke; W L Furlow
Journal:  J Urol       Date:  1981-01       Impact factor: 7.450

8.  Stereotactic radiosurgery for brain metastasis from renal cell carcinoma.

Authors:  Y Mori; D Kondziolka; J C Flickinger; T Logan; L D Lunsford
Journal:  Cancer       Date:  1998-07-15       Impact factor: 6.860

9.  Brain metastases from carcinoma of bladder.

Authors:  A D Steinfeld; M Zelefsky
Journal:  Urology       Date:  1987-04       Impact factor: 2.649

10.  Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group.

Authors:  A Bamias; Ch Deliveliotis; G Fountzilas; D Gika; A Anagnostopoulos; M P Zorzou; E Kastritis; C Constantinides; P Kosmidis; M A Dimopoulos
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

View more
  1 in total

1.  Central Nervous System Metastasis in Patients With Urothelial Carcinoma: Institutional Experience and a Comprehensive Review of the Literature.

Authors:  Leonidas N Diamantopoulos; Ali R Khaki; Guru P Sonpavde; Vyshak A Venur; Evan Y Yu; Jonathan L Wright; Petros Grivas
Journal:  Clin Genitourin Cancer       Date:  2019-12-05       Impact factor: 2.872

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.